Abstract
Xanthine oxidase, a key enzyme of purine metabolism, is considered to be a prime target for the treatment of hyperuricemia and oxidative stress related disorders. Allopurinol and febuxostat are two FDA approved xanthine oxidase inhibitors currently being used for management of chronic hyperuricemia. Plethora of natural sources has been explored in search of novel chemical templates for the development of antihyperuricemic drugs. Studies in past decade have shown the potential of endophytic fungi, which colonize the internal tissues of plants without any evident sign of their ubiquitous existence, as repository of novel chemical entities exhibiting antimicrobial, anti-oxidant, anti-inflammatory and anticancer potential. However, very scanty preliminary data is available of exploration of xanthine oxidase inhibitors from fungal endophytes. The present review summarizes the efficacy of xanthine oxidase as target for developing ant-gout agents and highlights the prospective of endophytic fungi as producers of xanthine oxidase inhibitors for the anti-hyperuricemic therapy regimen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
